Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00396227 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,665
- Enrollment target
NCT00396227 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,665 participants.
The verdict
NCT00396227, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,665 participants
- Enrollment target
Study Summary
This study is designed to evaluate, in a primary care setting, the safety and efficacy of vildaglipgtin as add on therapy to metformin relative to TZD added to metformin in patients with type 2 diabetes inadequately controlled by metformin alone.
Interventions
- DRUG vildagliptin
- DRUG thiazolidinedione (TZD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,665 participants |
| Start Date | 2006-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00396227
The ClinicalTrials.gov registry entry for NCT00396227 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,665 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vildagliptin is the first listed.
NCT00396227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00396227 about?
NCT00396227 is a clinical study titled "Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone". This study is designed to evaluate, in a primary care setting, the safety and efficacy of vildaglipgtin as add on therapy to metformin relative to TZD added to metformin in patients with type 2 diabetes inadequately controlled by metformin alone.
What is the current status of trial NCT00396227?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,665 participants. The study started on 2006-10.
What interventions are being tested in trial NCT00396227?
The interventions under investigation include: vildagliptin (DRUG), thiazolidinedione (TZD) (DRUG).
Who is sponsoring clinical trial NCT00396227?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.